{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:01:14Z","timestamp":1784761274210,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-043859"],"award-info":[{"award-number":["INV-043859"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-043859"],"award-info":[{"award-number":["INV-043859"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-043859"],"award-info":[{"award-number":["INV-043859"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-043859"],"award-info":[{"award-number":["INV-043859"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-043859"],"award-info":[{"award-number":["INV-043859"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","award":["GPLN\/OMD\/LoA\/2023\/3"],"award-info":[{"award-number":["GPLN\/OMD\/LoA\/2023\/3"]}],"id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The novel oral poliovirus vaccine type 2 (nOPV2) was developed to reduce the risk of circulating vaccine-derived poliovirus outbreaks by incorporating genetic modifications to enhance genetic stability and reduce reversion to virulence while retaining protection. Here we report the characterization of 231 nOPV2 isolates from Uganda during a 1-year period following nOPV2 use. Whole-genome sequencing revealed that most isolates retained nOPV2\u2019s genetic modifications, with limited mutations in the VP1 region indicating no relevant virus transmission. However, a double recombinant strain identified in a sewage sample lost all key nOPV2 modifications through recombination with enterovirus C strains upstream and downstream of the capsid coding region. This resulted in high neurovirulence comparable to that of wild-type 2 poliovirus. Despite this, the strain did not spread widely, probably due to high vaccination coverage. These findings underscore the enhanced genetic stability of nOPV2 and its reduced risk of reversion compared with Sabin monovalent OPV2 (mOPV2), while highlighting the importance of surveillance to detect rare recombination events. Continued use of nOPV2 and inactivated polio vaccine, combined with robust immunization and monitoring, remains essential for achieving and sustaining global polio eradication.<\/jats:p>","DOI":"10.1038\/s41564-025-02219-w","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:02:33Z","timestamp":1768816953000},"page":"406-414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Higher stability of novel live-attenuated oral poliovirus type 2 (nOPV2) despite the emergence of a neurovirulent double recombinant strain in Uganda"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0729-5505","authenticated-orcid":false,"given":"Phionah","family":"Tushabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasi","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Carlyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lester","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Ssekagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Line","family":"Joffret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Klapsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Cremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7972-3284","authenticated-orcid":false,"given":"Kafayat O.","family":"Arowolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Bujaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Bukenya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"EPI Laboratory team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Bridget","family":"Nanteza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Turyahabwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prossy","family":"Namuwulya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Birungi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Peter","family":"Eliku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Aine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayi","family":"Tibanagwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Nakabazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Gaizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold Mugagga","family":"Ssebuuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajab","family":"Dhatemwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Okia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Nyachwo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Bridget","family":"Nanteza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Turyahabwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prossy","family":"Namuwulya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Birungi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Peter","family":"Eliku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Aine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayi","family":"Tibanagwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Nakabazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Gaizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold Mugagga","family":"Ssebuuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajab","family":"Dhatemwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Okia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Nyachwo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Bridget","family":"Nanteza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Turyahabwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prossy","family":"Namuwulya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Birungi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Peter","family":"Eliku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Aine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayi","family":"Tibanagwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Nakabazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Gaizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold Mugagga","family":"Ssebuuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajab","family":"Dhatemwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Okia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Nyachwo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaija M.","family":"Hawes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnabas","family":"Bakamutumaho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Duizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mael","family":"Bessaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananda S.","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Macadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Byabamazima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5326-7081","authenticated-orcid":false,"given":"Javier","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6975-7106","authenticated-orcid":false,"given":"Josephine","family":"Bwogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"2219_CR1","unstructured":"Global Polio Eradication Initiative Polio Eradication Strategy 2022\u20132026: Delivering on a Promise (World Health Organization, 2021)."},{"key":"2219_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1126\/science.aba1238","volume":"368","author":"GR Macklin","year":"2020","unstructured":"Macklin, G. R. et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science 368, 401\u2013405 (2020).","journal-title":"Science"},{"key":"2219_CR3","doi-asserted-by":"publisher","first-page":"A142","DOI":"10.1016\/j.vaccine.2022.10.060","volume":"41","author":"DA Kalkowska","year":"2023","unstructured":"Kalkowska, D. A. et al. Outbreak response strategies with type 2-containing oral poliovirus vaccines. Vaccine 41, A142\u2013A152 (2023).","journal-title":"Vaccine"},{"key":"2219_CR4","doi-asserted-by":"publisher","first-page":"A79","DOI":"10.1016\/j.vaccine.2022.12.033","volume":"41","author":"A Afsar","year":"2023","unstructured":"Afsar, A. et al. Monovalent type 2 OPV (mOPV2) management in the field: interventions and lessons learned. Vaccine 41, A79\u2013A84 (2023).","journal-title":"Vaccine"},{"key":"2219_CR5","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.chom.2020.04.003","volume":"27","author":"MT Yeh","year":"2020","unstructured":"Yeh, M. T. et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe 27, 736\u201351.e8 (2020).","journal-title":"Cell Host Microbe"},{"key":"2219_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(20)32541-1","volume":"397","author":"I De Coster","year":"2021","unstructured":"De Coster, I. et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet 397, 39\u201350 (2021).","journal-title":"Lancet"},{"key":"2219_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00437-5","volume":"7","author":"R Wahid","year":"2022","unstructured":"Wahid, R. et al. Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children. NPJ Vaccines. 7, 19 (2022).","journal-title":"NPJ Vaccines."},{"key":"2219_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00355-y","volume":"6","author":"R Wahid","year":"2021","unstructured":"Wahid, R. et al. Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses. NPJ Vaccines. 6, 94 (2021).","journal-title":"NPJ Vaccines."},{"key":"2219_CR9","unstructured":"Global Polio Eradication Initiative Novel Oral Polio Vaccine Type 2 (nOPV2) Granted EUL Recommendation (World Health Organization, 2020)."},{"key":"2219_CR10","doi-asserted-by":"publisher","first-page":"A122","DOI":"10.1016\/j.vaccine.2022.02.050","volume":"41","author":"GR Macklin","year":"2023","unstructured":"Macklin, G. R. et al. Enabling accelerated vaccine roll-out for public health emergencies of international concern (PHEICs): novel oral polio vaccine type 2 (nOPV2) experience. Vaccine 41, A122\u2013A127 (2023).","journal-title":"Vaccine"},{"key":"2219_CR11","unstructured":"Global Polio Eradication Initiative GPEI nOPV2 Working Group Structure and Linkages (World Health Organization, 2020)."},{"key":"2219_CR12","doi-asserted-by":"publisher","first-page":"786","DOI":"10.15585\/mmwr.mm7124a2","volume":"71","author":"J Martin","year":"2022","unstructured":"Martin, J. et al. Genetic characterization of novel oral polio vaccine type 2 viruses during initial use phase under emergency use listing\u2014worldwide, March\u2013October 2021. MMWR Morb. Mortal. Wkly Rep. 71, 786\u2013790 (2022).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"2219_CR13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s00705-023-05759-w","volume":"168","author":"P Tushabe","year":"2023","unstructured":"Tushabe, P. et al. Environmental surveillance detects circulating vaccine-derived poliovirus type 2 that was undetected by acute flaccid paralysis surveillance in 2021 in Uganda. Arch. Virol. 168, 140 (2023).","journal-title":"Arch. Virol."},{"key":"2219_CR14","unstructured":"Uganda National Expanded Program on Immunization nOPV2 Campaigns Round 1: Round 1 Supplementary Immunization Activity (SIAs) Polio Campaign Report (Ministry of Health Uganda, 2022); https:\/\/library.health.go.ug\/communicable-disease\/vaccination-and-immunisation-unepi\/round-1-supplementary-immunization-activity"},{"key":"2219_CR15","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.15585\/mmwr.mm7238a4","volume":"72","author":"E Davlantes","year":"2023","unstructured":"Davlantes, E. et al. Notes from the field: circulating vaccine-derived poliovirus type 2 emergences linked to novel oral poliovirus vaccine type 2 use\u2014six African countries, 2021\u20132023. MMWR Morb. Mortal. Wkly Rep. 72, 1041\u20131042 (2023).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"2219_CR16","doi-asserted-by":"publisher","first-page":"909","DOI":"10.15585\/mmwr.mm7341a1","volume":"73","author":"A Namageyo-Funa","year":"2024","unstructured":"Namageyo-Funa, A. et al. Update on vaccine-derived poliovirus outbreaks\u2014worldwide, January 2023\u2013June 2024. MMWR Morb. Mortal. Wkly Rep. 73, 909\u2013916 (2024).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"2219_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/mra.00881-24","volume":"13","author":"CJ Castro","year":"2024","unstructured":"Castro, C. J. et al. Complete genome sequences of nine double recombinant vaccine-derived novel oral poliovirus type 2 genomes from Nigeria 2023\u20132024. Microbiol. Resour. Announc. 13, e0088124 (2024).","journal-title":"Microbiol. Resour. Announc."},{"key":"2219_CR18","unstructured":"Uganda Reported Cases of Vaccine-Preventable Diseases (VPDs) (WHO, 2024)."},{"key":"2219_CR19","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3390\/vaccines12121308","volume":"12","author":"CM Peak","year":"2024","unstructured":"Peak, C. M. et al. Monitoring the risk of type-2 circulating vaccine-derived poliovirus emergence during roll-out of type-2 novel oral polio vaccine. Vaccines 12, 1308 (2024).","journal-title":"Vaccines"},{"key":"2219_CR20","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3390\/v11090859","volume":"11","author":"C Muslin","year":"2019","unstructured":"Muslin, C., Mac Kain, A., Bessaud, M., Blondel, B. & Delpeyroux, F. Recombination in enteroviruses, a multi-step modular evolutionary process. Viruses 11, 859 (2019).","journal-title":"Viruses"},{"key":"2219_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07826-0","volume":"22","author":"R Razafindratsimandresy","year":"2022","unstructured":"Razafindratsimandresy, R. et al. Enterovirus detection in different regions of Madagascar reveals a higher abundance of enteroviruses of species C in areas where several outbreaks of vaccine-derived polioviruses occurred. BMC Infect. Dis. 22, 821 (2022).","journal-title":"BMC Infect. Dis."},{"key":"2219_CR22","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3390\/v13030434","volume":"13","author":"L Brouwer","year":"2021","unstructured":"Brouwer, L., Moreni, G., Wolthers, K. C. & Pajkrt, D. World-wide prevalence and genotype distribution of enteroviruses. Viruses 13, 434 (2021).","journal-title":"Viruses"},{"key":"2219_CR23","unstructured":"Polio Laboratory Manual 4th edn (World Health Organization, 2004)."},{"key":"2219_CR24","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1093\/cid\/ciy638","volume":"67","author":"G Matrajt","year":"2018","unstructured":"Matrajt, G., Naughton, B., Bandyopadhyay, A. S. & Meschke, J. S. A review of the most commonly used methods for sample collection in environmental surveillance of poliovirus. Clin. Infect. Dis. 67, S90\u2013S97 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"2219_CR25","unstructured":"Guidelines for Environmental Surveillance of Poliovirus Circulation (World Health Organization, 2003)."},{"key":"2219_CR26","doi-asserted-by":"publisher","first-page":"e01624-17","DOI":"10.1128\/JCM.01624-17","volume":"56","author":"N Gerloff","year":"2018","unstructured":"Gerloff, N. et al. Diagnostic assay development for poliovirus eradication. J. Clin. Microbiol. 56, e01624-17 (2018).","journal-title":"J. Clin. Microbiol."},{"key":"2219_CR27","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0140-6736(22)01804-9","volume":"400","author":"D Klapsa","year":"2022","unstructured":"Klapsa, D. et al. Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance. Lancet 400, 1531\u20131538 (2022).","journal-title":"Lancet"},{"key":"2219_CR28","doi-asserted-by":"publisher","unstructured":"Arowolo, K. K. D., Majumdar, M., Bujaki, E., Tedcastle, A. & Martin, J. Tiled PCR amplification for poliovirus whole-genome sequencing. protocols.io https:\/\/doi.org\/10.17504\/protocols.io.5qpvowjr7l4o\/v1 (2025).","DOI":"10.17504\/protocols.io.5qpvowjr7l4o\/v1"},{"key":"2219_CR29","doi-asserted-by":"crossref","unstructured":"Majumdar, M. et al. Isolation of vaccine-like poliovirus strains in sewage samples from the United Kingdom. J. Infect. Dis. 217, 1222\u20131230 (2018).","DOI":"10.1093\/infdis\/jix667"},{"key":"2219_CR30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3390\/v13020249","volume":"13","author":"M Majumdar","year":"2021","unstructured":"Majumdar, M. et al. High diversity of human non-polio enterovirus serotypes identified in contaminated water in Nigeria. Viruses 13, 249 (2021).","journal-title":"Viruses"},{"key":"2219_CR31","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3389\/fmicb.2018.01956","volume":"9","author":"M Majumdar","year":"2018","unstructured":"Majumdar, M. & Martin, J. Detection by direct next generation sequencing analysis of emerging enterovirus D68 and C109 strains in an environmental sample from Scotland. Front. Microbiol. 9, 1956 (2018).","journal-title":"Front. Microbiol."},{"key":"2219_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy250","volume":"5","author":"M Majumdar","year":"2018","unstructured":"Majumdar, M. et al. Environmental surveillance reveals complex enterovirus circulation patterns in human populations. Open Forum Infect. Dis. 5, ofy250 (2018).","journal-title":"Open Forum Infect. Dis."},{"key":"2219_CR33","doi-asserted-by":"publisher","first-page":"e1005316","DOI":"10.1371\/journal.ppat.1005316","volume":"11","author":"S Knowlson","year":"2015","unstructured":"Knowlson, S. et al. New strains intended for the production of inactivated polio vaccine at low-containment after eradication. PLoS Pathog. 11, e1005316 (2015).","journal-title":"PLoS Pathog."},{"key":"2219_CR34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0022-2836(05)80360-2","volume":"215","author":"SF Altschul","year":"1990","unstructured":"Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. J. Mol. Biol. 215, 403\u2013410 (1990).","journal-title":"J. Mol. Biol."},{"key":"2219_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jcv.2011.03.006","volume":"51","author":"A Kroneman","year":"2011","unstructured":"Kroneman, A. et al. An automated genotyping tool for enteroviruses and noroviruses. J. Clin. Virol. 51, 121\u2013125 (2011).","journal-title":"J. Clin. Virol."},{"key":"2219_CR36","unstructured":"Code of Practice for the Housing and Care of Animals Bred, Supplied or Used for Scientific Purposes (UK Home Office, 2014)."},{"key":"2219_CR37","unstructured":"Neurovirulence Test of Types 1, 2 or 3 Live Attenuated Poliomyelitis Vaccines (Oral) in Transgenic Mice Susceptible to Poliovirus (World Health Organization, 2015)."},{"key":"2219_CR38","doi-asserted-by":"crossref","unstructured":"K\u00e4rber, G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn Schmiedebergs Arch. Exp. Pathol. Pharmakol. 162, 480\u2013483 (1931).","DOI":"10.1007\/BF01863914"}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-02219-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-02219-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-02219-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:03:03Z","timestamp":1770217383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-02219-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["2219"],"URL":"https:\/\/doi.org\/10.1038\/s41564-025-02219-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6473472\/v1","asserted-by":"object"}]},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research was conducted through an inclusive and collaborative partnership involving institutions across Uganda, the United Kingdom, Israel, France, the Netherlands, the United States and the World Health Organization. The study reflects a shared commitment to global public health, scientific integrity and equitable collaboration. Local expertise at the Uganda Virus Research Institute and the EPI Laboratory team played a central role in sample collection, processing and virus isolation, ensuring contextual relevance and contributing to capacity strengthening.The study did not involve human participants, but the analysis of viral nucleotide sequences involved viral isolates recovered from anonymous clinical (stools) and environmental (sewage) samples. Clinical and environmental specimens analysed in this study were collected as part of routine public health surveillance under the GPEI. AFP surveillance and environmental sampling are core components of Uganda\u2019s National Poliovirus Surveillance programme, implemented by the Ministry of Health with technical support from the World Health Organization. These surveillance activities follow WHO-recommended protocols and are classified as non-research public health activities that do not require individual informed consent. The Uganda Virus Research Institute, serving as the National Polio Laboratory, conducted specimen processing and virus isolation under standard WHO procedures. Only de-identified poliovirus isolates were transferred for sequencing and genomic analysis. No personally identifiable information was collected or analysed; the only human-derived metadata retained were sample collection dates, used solely for epidemiological context. The study did not involve human participants research as defined by international ethics guidelines, and all analyses were limited to viral genomic sequences. Ethics oversight was provided by national authorities, and all activities complied with relevant ethics standards for the secondary use of surveillance-derived human specimens in global public health research.Animal work was approved by MHRA\u2019s Ethics and Human Materials Advisory Committees. MHRA\u2019s Animal Welfare and Ethical Review Body approved the application for Procedure Project Licence Number PPL PP6108158, which was approved by the UK Government Home Office and under which animal care and protocols shown in this paper were conducted. All animal care and protocols used at MHRA adhere to the UK Animals (Scientific Procedures) Act 1986 and the Home Office Code of Practice for the Housing and Care of Animals Bred, Supplied or Used for Scientific Purposes.All authors contributed to the research and writing process with mutual respect for diverse expertise, fostering transparency, inclusivity and shared ownership. The study aligns with principles of responsible data use, equitable access to research opportunities and the global effort to eliminate poliovirus transmission through open, cross-border scientific cooperation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Inclusion and ethics statement"}}]}}